The STAMBP protein has been reported as a potential diagnostic biomarker for early Alzheimer ‘s disease (Whelan et al., 2019), late pregnancy in women with postpartum depression (Bränn et al., 2017), fibromyalgia (Fineschi et al., 2022), and esophageal squamous cell carcinoma (Aversa et al., 2020). This evidence concerns the gene STAMBP and fibromyalgia.